Beth Israel Deaconess Med Center is a clinical research site located in Boston, Massachusetts, United States 02215.
Crixeo Health Trust Score: 71/100 (FAIR). This profile has not yet been claimed by the site owner.
Beth Israel Deaconess Med Center has participated in 9 clinical trials with 6 currently active.
Therapeutic areas: Primary Immune Thrombocytopenia (ITP), Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program, Hidradenitis Suppurativa.
Sponsors: Novartis Pharmaceuticals, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
Trust Score: 71/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Beth Israel Deaconess Med Center has a Crixeo Trust Score of 71/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Beth Israel Deaconess Med Center has 9 clinical trials on record, with 6 currently active. Their work covers Primary Immune Thrombocytopenia (ITP), Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program, Hidradenitis Suppurativa.
Yes — Beth Israel Deaconess Med Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.